Changes in diffuse optical tomography images during early stages of neoadjuvant chemotherapy correlate with tumor response in different breast cancer subtypes

Mirella L. Altoe, Kevin Kalinsky, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Dawn L. Hershman, Andreas H. Hielscher

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Purpose: This study's primary objective was to evaluate the changes in optically derived parameters acquired with a diffuse optical tomography breast imaging system (DOTBIS) in the tumor volume of patients with breast carcinoma receiving neoadjuvant chemotherapy (NAC). Experimental Design: In this analysis of 105 patients with stage II-III breast cancer, normalized mean values of total hemoglobin (ctTHbN), oxyhemoglobin (ctO2HbN), deoxy-hemoglobin concentration (ctHHbN), water, and oxygen saturation (StO2N) percentages were collected at different timepoints during NAC and compared with baseline measurements. This report compared changes in these optical biomarkers measured in patients who did not achieve a pathologic complete response (non-pCR) and those with a pCR. Differences regarding molecular subtypes were included for hormone receptor-positive and HER2-negative, HER2-positive, and triple-negative breast cancer. Results: At baseline, ctHHbN was higher for pCR tumors (3.97 ± 2.29) compared with non-pCR tumors (3.00 ± 1.72; P = 0.031). At the earliest imaging point after starting therapy, the mean change of ctHHbN compared with baseline (DTP1ctHHbN) was statistically significantly higher in non-pCR (1.23 ± 0.67) than in those with a pCR (0.87 ± 0.61; P < 0.0005), and significantly correlated to residual cancer burden classification (r = 0.448; P < 0.0005). DTP1ctHHbN combined with HER2 status was proposed as a two-predictor logistic model, with AUC = 0.891; P < 0.0005; and 95% confidence interval, 0.812-0.969. Conclusions: This study demonstrates that DOTBIS measured features change over time according to tumor pCR status and may predict early in the NAC treatment course whether a patient is responding to NAC.

    Original languageEnglish (US)
    Pages (from-to)1949-1957
    Number of pages9
    JournalClinical Cancer Research
    Volume27
    Issue number7
    DOIs
    StatePublished - Apr 2021

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Changes in diffuse optical tomography images during early stages of neoadjuvant chemotherapy correlate with tumor response in different breast cancer subtypes'. Together they form a unique fingerprint.

    Cite this